Clinical Trial Update: Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial comparing metabolic responses of dapagliflozin versus sitagliptin in Type 2 Diabetes patients inadequately controlled with insulin therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• Sitagliptin (sitagliptin)

Snippet

Sponsor: The University of Hong Kong | Conditions: Type 2 Diabetes, Ketonemia | Phase 4 | Status: COMPLETED